Clinical trial
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving…
NCT00245050 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00245050 |
|---|---|
| Title | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
| Official title | A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Dietary Supplement, Drug |
| Interventions | pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome |
| Enrollment | 34 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Sep 1, 2011 |
| First posted | Oct 27, 2005 |
| Last update posted | Dec 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: